See more : CS Holdings Co., Ltd. (000590.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Milestone Pharmaceuticals Inc. (MIST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Milestone Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- e-therapeutics plc (ETX.L) Income Statement Analysis – Financial Results
- Moatable, Inc. (MTBL) Income Statement Analysis – Financial Results
- Ashland Inc. (ASH) Income Statement Analysis – Financial Results
- SK IE Technology Co., Ltd. (361610.KS) Income Statement Analysis – Financial Results
- Austral Gold Limited (AGD.AX) Income Statement Analysis – Financial Results
Milestone Pharmaceuticals Inc. (MIST)
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.00M | 5.00M | 15.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 480.00K | 0.00 | 376.00K | 236.00K | 10.00K | 8.00K |
| Gross Profit | 1.00M | 4.52M | 15.00M | -376.00K | -236.00K | -10.00K | -8.00K |
| Gross Profit Ratio | 100.00% | 90.40% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31.05M | 39.83M | 38.67M | 34.49M | 41.99M | 16.85M | 5.64M |
| General & Administrative | 15.93M | 15.72M | 12.40M | 10.29M | 7.00M | 3.05M | 1.50M |
| Selling & Marketing | 15.11M | 9.10M | 7.00M | 5.94M | 8.89M | 3.92M | 1.13M |
| SG&A | 31.05M | 24.81M | 19.40M | 16.22M | 15.90M | 6.97M | 2.63M |
| Other Expenses | 0.00 | 0.00 | 7.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 62.10M | 64.64M | 58.07M | 50.71M | 57.88M | 23.82M | 8.27M |
| Cost & Expenses | 62.10M | 64.64M | 58.07M | 50.71M | 57.88M | 23.82M | 8.27M |
| Interest Income | 3.97M | 1.25M | 220.00K | 726.00K | 2.60M | 711.00K | 186.00K |
| Interest Expense | 2.55M | 0.00 | 0.00 | 726.00K | 2.60M | 0.00 | 0.00 |
| Depreciation & Amortization | 92.00K | 480.00K | 362.00K | 376.00K | 236.00K | 10.00K | 8.00K |
| EBITDA | -56.85M | -58.36M | -42.98M | -50.71M | -57.88M | -23.36M | -8.26M |
| EBITDA Ratio | -5,684.50% | -1,192.84% | -286.53% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -61.10M | -59.64M | -43.07M | -50.71M | -57.88M | -23.82M | -8.27M |
| Operating Income Ratio | -6,109.80% | -1,192.84% | -287.15% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.41M | 1.25M | 220.00K | 726.00K | 2.60M | 711.00K | 186.00K |
| Income Before Tax | -59.69M | -58.39M | -42.85M | -49.98M | -55.29M | -23.11M | -8.08M |
| Income Before Tax Ratio | -5,968.50% | -1,167.76% | -285.69% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.25M | -220.00K | -17.00K | -56.00K | 74.00K | 4.00K |
| Net Income | -59.69M | -57.13M | -42.63M | -49.97M | -55.23M | -23.19M | -8.09M |
| Net Income Ratio | -5,968.50% | -1,142.68% | -284.22% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.39 | -1.35 | -1.02 | -1.70 | -3.50 | -0.98 | -0.34 |
| EPS Diluted | -1.39 | -1.35 | -1.02 | -1.70 | -3.50 | -0.98 | -0.34 |
| Weighted Avg Shares Out | 42.96M | 42.45M | 41.83M | 29.34M | 15.78M | 23.65M | 23.65M |
| Weighted Avg Shares Out (Dil) | 42.96M | 42.45M | 41.83M | 29.34M | 15.78M | 23.65M | 23.65M |
Milestone Pharmaceuticals: Potential NDA Submission Of Etripamil Catalyst Set For Mid-2023
Etripamil succeeded in phase 3 RAPID study, Milestone in talks with FDA to possibly file an NDA for this drug in treating PSVT patients by mid-2023. It is said that there are about 2 million PSVT patients in the United...
Milestone Pharmaceuticals: Looking Attractive After Drop On Positive News
Milestone Pharmaceuticals reported positive data from the RAPID arm of its pivotal trial. After an initial premarket spurt, the stock dropped drastically.
Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 42.9% in 4 Weeks
Milestone Pharmaceuticals (MIST) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Milestone's (MIST) Tachycardia Study Data Fail to Impress Investors
Milestone (MIST) reports positive top-line results from its late-stage study evaluating its lead candidate, etripamil, in patients with paroxysmal supraventricular tachycardia. The results fail to impress investors.
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., Nov. 11, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor...
Milestone Pharmaceuticals to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
MONTREAL and CHARLOTTE, N.C., Sept. 22, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Amit Hasija, Chief Financial Officer and Executive Vice President of Corporate Development, will present at...
Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., Aug. 11, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, 2021 and provided a clinical and corporate...
Milestone Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
MONTREAL and CHARLOTTE, N.C., May 26, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference...
Week In Review: LianBio Acquires 2 IBD Candidates In $218 Million Deal
LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. Ji Xing Pharma of Shanghai acquired Greater China rights to a novel treatment for tachycardia from Milestone Pharma in a $127.5 million agreement.
Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21
- Statistically Significant Improvements in PSVT-Associated Symptoms and Less ER Visits Observed in Patients Treated with Etripamil Compared to Placebo in the NODE-301 Trial - - Data Presented at the American College of Cardiology's 70th Annual Scientific Session - MONTREAL and Charlotte,...
Source: https://incomestatements.info
Category: Stock Reports